Stock News

Bard Associates Cut Its Position in Envirostar (EVI) by $4.50 Million as Valuation Rose; Healthinvest Partners Ab Position in Gilead Sciences (GILD) Decreased by $2.88 Million

EnviroStar, Inc. (NYSEAMERICAN:EVI) Logo

Bard Associates Inc decreased its stake in Envirostar Inc (EVI) by 66.47% based on its latest 2017Q4 regulatory filing with the SEC. Bard Associates Inc sold 112,401 shares as the company’s stock rose 9.87% while stock markets declined. The institutional investor held 56,700 shares of the consumer services company at the end of 2017Q4, valued at $2.27 million, down from 169,101 at the end of the previous reported quarter. Bard Associates Inc who had been investing in Envirostar Inc for a number of months, seems to be less bullish one the $443.94 million market cap company. The stock decreased 0.50% or $0.2 during the last trading session, reaching $39.8. About 2,358 shares traded. EnviroStar, Inc. (NYSEMKT:EVI) has risen 101.58% since May 17, 2017 and is uptrending. It has outperformed by 90.03% the S&P500.

Anders Hallberg decreased its stake in Gilead Sciences Inc (GILD) by 52.87% based on its latest 2017Q4 regulatory filing with the SEC. Healthinvest Partners Ab sold 40,500 shares as the company’s stock rose 1.93% while stock markets declined. The hedge fund run by Anders Hallberg held 36,100 shares of the health care company at the end of 2017Q4, valued at $2.59M, down from 76,600 at the end of the previous reported quarter. Healthinvest Partners Ab who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $88.15 billion market cap company. The stock increased 0.36% or $0.24 during the last trading session, reaching $67.79. About 2.19M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 EPS, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86 billion for 11.85 P/E if the $1.43 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It turned negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Amf Pensionsforsakring Ab owns 1.26 million shares or 0.88% of their US portfolio. Winfield Assocs owns 305 shares for 0.01% of their portfolio. State Of Wisconsin Inv Board has invested 0.38% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Moors And Cabot invested 0.23% in Gilead Sciences, Inc. (NASDAQ:GILD). St Germain D J invested in 0.03% or 3,498 shares. Oregon Pub Employees Retirement Fund holds 0.96% or 736,713 shares in its portfolio. Cs Mckee LP has invested 0.78% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Lipe Dalton accumulated 49,425 shares. First Manhattan Com reported 1.09% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Benedict Advisors owns 24,341 shares. Cap Sarl, a California-based fund reported 33,700 shares. Com Retail Bank invested in 54,209 shares or 0.05% of the stock. Prudential Public Limited Company accumulated 3.41 million shares. Wealthtrust Axiom Ltd Liability reported 0.51% stake. Of Oklahoma invested in 8,731 shares.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” on May 16, 2018, also Seekingalpha.com with their article: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” published on May 15, 2018, Seekingalpha.com published: “Gilead: What A Disaster” on May 08, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Atara Biotherapeutics: A Gift That Keeps On Giving” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Kite Pharma continues buildout for cell therapy manufacture” with publication date: May 15, 2018.

Since January 2, 2018, it had 0 insider buys, and 22 sales for $44.80 million activity. $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Meyers James R on Tuesday, January 16. Shares for $440,741 were sold by Cogan John Francis on Friday, April 13. Another trade for 60,000 shares valued at $4.68M was made by WILSON GAYLE E on Friday, February 9. 25,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $2.09 million were sold by Alton Gregg H. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Washington Robin L.

EnviroStar, Inc. (NYSEAMERICAN:EVI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *